118 related articles for article (PubMed ID: 12034101)
1. DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine.
Klinguer-Hamour C; Libon C; Plotnicky-Gilquin H; Bussat MC; Revy L; Nguyen T; Bonnefoy JY; Corvaïa N; Beck A
Vaccine; 2002 Jun; 20(21-22):2743-51. PubMed ID: 12034101
[TBL] [Abstract][Full Text] [Related]
2. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
[TBL] [Abstract][Full Text] [Related]
3. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
[TBL] [Abstract][Full Text] [Related]
4. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
Lambert SL; Aslam S; Stillman E; MacPhail M; Nelson C; Ro B; Sweetwood R; Lei YM; Woo JC; Tang RS
PLoS One; 2015; 10(3):e0119509. PubMed ID: 25793508
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
[TBL] [Abstract][Full Text] [Related]
6. A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice.
Céspedes PF; Rey-Jurado E; Espinoza JA; Rivera CA; Canedo-Marroquín G; Bueno SM; Kalergis AM
Vaccine; 2017 Feb; 35(5):757-766. PubMed ID: 28065474
[TBL] [Abstract][Full Text] [Related]
7. The immunogenicity, protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) vaccine candidate, against RSV-B.
Power UF; Plotnicky H; Blaecke A; Nguyen TN
Vaccine; 2003 Dec; 22(2):168-76. PubMed ID: 14615143
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-27 inhibits vaccine-enhanced pulmonary disease following respiratory syncytial virus infection by regulating cellular memory responses.
Zeng R; Zhang H; Hai Y; Cui Y; Wei L; Li N; Liu J; Li C; Liu Y
J Virol; 2012 Apr; 86(8):4505-17. PubMed ID: 22301139
[TBL] [Abstract][Full Text] [Related]
9. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.
Hwang HS; Lee YT; Kim KH; Park S; Kwon YM; Lee Y; Ko EJ; Jung YJ; Lee JS; Kim YJ; Lee YN; Kim MC; Cho M; Kang SM
Virology; 2016 Jul; 494():215-24. PubMed ID: 27123586
[TBL] [Abstract][Full Text] [Related]
10. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.
Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H
Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271
[TBL] [Abstract][Full Text] [Related]
11. Protection against respiratory syncytial virus infection by DNA immunization.
Li X; Sambhara S; Li CX; Ewasyshyn M; Parrington M; Caterini J; James O; Cates G; Du RP; Klein M
J Exp Med; 1998 Aug; 188(4):681-8. PubMed ID: 9705950
[TBL] [Abstract][Full Text] [Related]
12. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
[TBL] [Abstract][Full Text] [Related]
13. Lipopolysaccharide Inhibits FI-RSV Vaccine-enhanced Inflammation Through Regulating Th Responses.
Yin W; Li HY; Zheng BY; Deng YQ; Li WJ; Liu Y; Zeng RH
Curr Med Sci; 2019 Jun; 39(3):363-370. PubMed ID: 31209804
[TBL] [Abstract][Full Text] [Related]
14. HRSV prefusion-F protein with Adju-Phos adjuvant induces long-lasting Th2-biased immunity in mice.
Li H; Ren H; Zhou Y; Zhang Y; Cao L; Xu W
PLoS One; 2022; 17(1):e0262231. PubMed ID: 35100303
[TBL] [Abstract][Full Text] [Related]
15. CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice.
Harcourt JL; Brown MP; Anderson LJ; Tripp RA
Vaccine; 2003 Jun; 21(21-22):2964-79. PubMed ID: 12798640
[TBL] [Abstract][Full Text] [Related]
16. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
[TBL] [Abstract][Full Text] [Related]
17. A Built-In CpG Adjuvant in RSV F Protein DNA Vaccine Drives a Th1 Polarized and Enhanced Protective Immune Response.
Ma Y; Jiao YY; Yu YZ; Jiang N; Hua Y; Zhang XJ; Fu YH; Peng XL; Zheng YP; Anderson LJ; He JS
Viruses; 2018 Jan; 10(1):. PubMed ID: 29342954
[TBL] [Abstract][Full Text] [Related]
18. Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2.
Zeng R; Qi X; Gong W; Mei X; Wei L; Ma C; Yin X
Vaccine; 2007 Oct; 25(42):7422-8. PubMed ID: 17850930
[TBL] [Abstract][Full Text] [Related]
19. Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2NA, in aluminum hydroxide.
Corvaïa N; Tournier P; Nguyen TN; Haeuw JF; Power UF; Binz H; Andréoni C
J Infect Dis; 1997 Sep; 176(3):560-9. PubMed ID: 9291300
[TBL] [Abstract][Full Text] [Related]
20. Nucleoprotein nanostructures combined with adjuvants adapted to the neonatal immune context: a candidate mucosal RSV vaccine.
Remot A; Roux X; Dubuquoy C; Fix J; Bouet S; Moudjou M; Eléouët JF; Riffault S; Petit-Camurdan A
PLoS One; 2012; 7(5):e37722. PubMed ID: 22655066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
